Menopause care is one of the most active corners of digital health right now. Midi Health, Alloy, Elektra Health, Stella, Winona, and a long tail of new VC-backed entrants are racing to serve a patient population that most of healthcare has spent decades ignoring.
We've had a front-row seat to this rise at our company Bridge, where we help virtual care providers across the industry access in-network coverage. Menopause has been one of our fastest-growing segments, and in this piece, we'll explain why. Patient demand is huge, but demand alone doesn't explain the boom.
Three forces explain the rapid rise:
Hormone replacement therapy no longer carries fear-inducing warning labels.
Treating menopause is no longer taboo.
Menopause care is unusually well-suited to virtual care.
Together, they explain why the founders who arrived first and built durable, evidence-based practices are sitting on some of the most valuable patient relationships in women's health. Menopause is what we internally refer to as a digital health “triple threat.”
Reserve Your Spot for Upcoming Webinars!
Webinar Topic | Panelists’ | Timing | Registration |
|---|---|---|---|
Freeing Data From the EHR | Lisa Bari, | June 17th, 2026 | |
Not everyone can access the Top 1% of physicians. Will AI change that? | Daniel Stein | June 23rd, 2026 |
The clinical reset
The clinical reset is a reversal of a 20-year mistake. The findings published in 2002 by the Women's Health Initiative scared a generation away from hormone replacement therapy (HRT) after falsely linking it to elevated cardiovascular disease, breast cancer, and dementia risks.
The study was built on existing evidence that HRT benefits women who start near menopause. Its goal was to test whether those benefits extended to women who started later, so the enrolled population skewed older than the typical patient starting HRT. The absolute risk numbers were small, but were reported in relative terms, making them sound enormous. Prescription rates cratered.
As a result, a generation of women lived through hot flashes, brain fog, sleep loss, and bone density decline because their doctors — and they themselves — had been told the alternative was dangerous. Since then, reassessments of the data have told a different story: for most women in early stages of perimenopause or menopause, the benefits of starting HRT substantially outweigh the risks.
The consensus has now caught up, but it’s taken time. Several of the most important shifts in thinking were only recently implemented. In 2024, the American College of Obstetricians and Gynecologists reaffirmed Practice Bulletin No. 141, supporting HRT as the most effective therapy for vasomotor symptoms in symptomatic women under 60 within 10 years of menopause onset. In November 2025, the Food and Drug Administration, the agency that had scared women by placing the Black Box Warning on all estrogen products, announced that it was removing those warnings from six menopausal HRT products.
Change is moving slowly, even with consensus shifting. Only a third of relevant medical residency programs have a menopause curriculum, according to a 2023 survey of U.S. OB/GYN residency program directors published in Menopause. Most practicing OB/GYNs report feeling unprepared to manage symptoms beyond basic counseling. Patients often leave a 12-minute office visit with an SSRI, a "wait it out" recommendation, or no prescription at all. The system is failing them. By the time women turn to a virtual menopause clinic, their patience has run out.